207 related articles for article (PubMed ID: 26663686)
1. Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients.
Peters KM; Jayabalan N; Bui D; Killinger K; Chancellor M; Tyagi P
Low Urin Tract Symptoms; 2015 May; 7(2):77-83. PubMed ID: 26663686
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre.
Gajewski JB; Al-Zahrani AA
BJU Int; 2011 Apr; 107(8):1258-64. PubMed ID: 20883483
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis.
Maher CF; Carey MP; Dwyer PL; Schluter PL
J Urol; 2001 Mar; 165(3):884-6. PubMed ID: 11176493
[TBL] [Abstract][Full Text] [Related]
4. Urine nerve growth factor (NGF) level, bladder nerve staining and symptom/problem scores in patients with interstitial cystitis.
Tonyali S; Ates D; Akbiyik F; Kankaya D; Baydar D; Ergen A
Adv Clin Exp Med; 2018 Feb; 27(2):159-163. PubMed ID: 29521057
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up.
Ghazwani YQ; Elkelini MS; Hassouna MM
Neurourol Urodyn; 2011 Sep; 30(7):1271-5. PubMed ID: 21557299
[TBL] [Abstract][Full Text] [Related]
6. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
[TBL] [Abstract][Full Text] [Related]
7. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study.
Comiter CV
J Urol; 2003 Apr; 169(4):1369-73. PubMed ID: 12629364
[TBL] [Abstract][Full Text] [Related]
8. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.
Rahnama'i MS; Marcelissen T; Apostolidis A; Veit-Rubin N; Schurch B; Cardozo L; Dmochowski R
Neurourol Urodyn; 2018 Jun; 37(S4):S99-S107. PubMed ID: 29363792
[TBL] [Abstract][Full Text] [Related]
10. Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis.
Peters KM; Konstandt D
BJU Int; 2004 Apr; 93(6):777-9. PubMed ID: 15049989
[TBL] [Abstract][Full Text] [Related]
11. Secondary changes in bowel function after successful treatment of voiding symptoms with neuromodulation.
Killinger KA; Kangas JR; Wolfert C; Boura JA; Peters KM
Neurourol Urodyn; 2011 Jan; 30(1):133-7. PubMed ID: 20928914
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature.
Mahran A; Baaklini G; Hassani D; Abolella HA; Safwat AS; Neudecker M; Hijaz AK; Mahajan ST; Siegel SW; El-Nashar SA
Int Urogynecol J; 2019 Jul; 30(7):1023-1035. PubMed ID: 30874835
[TBL] [Abstract][Full Text] [Related]
13. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management.
Nickel JC; Shoskes D; Irvine-Bird K
J Urol; 2009 Jul; 182(1):155-60. PubMed ID: 19447429
[TBL] [Abstract][Full Text] [Related]
14. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment.
Liu HT; Tyagi P; Chancellor MB; Kuo HC
BJU Int; 2009 Nov; 104(10):1476-81. PubMed ID: 19522864
[TBL] [Abstract][Full Text] [Related]
15. Improving clinical outcomes with lower motor voltage (≤3 V) during stage 1 sacral neuromodulation for interstitial cystitis or bladder pain syndrome.
Marinkovic SP
Neurourol Urodyn; 2019 Nov; 38(8):2233-2241. PubMed ID: 31512775
[TBL] [Abstract][Full Text] [Related]
16. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens.
Corcoran AT; Yoshimura N; Tyagi V; Jacobs B; Leng W; Tyagi P
World J Urol; 2013 Feb; 31(1):241-6. PubMed ID: 22441309
[TBL] [Abstract][Full Text] [Related]
17. Sacral Neuromodulation for Refractory Bladder Pain Syndrome/Interstitial Cystitis: a Global Systematic Review and Meta-analysis.
Wang J; Chen Y; Chen J; Zhang G; Wu P
Sci Rep; 2017 Sep; 7(1):11031. PubMed ID: 28887515
[TBL] [Abstract][Full Text] [Related]
18. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis.
Tyagi P; Killinger K; Tyagi V; Nirmal J; Chancellor M; Peters KM
J Urol; 2012 Jun; 187(6):2243-8. PubMed ID: 22503040
[TBL] [Abstract][Full Text] [Related]
19. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics.
Jiang YH; Jhang JF; Hsu YH; Ho HC; Wu YH; Kuo HC
Am J Physiol Renal Physiol; 2020 Jun; 318(6):F1391-F1399. PubMed ID: 32281420
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures.
Powell CR; Kreder KJ
J Urol; 2010 Jan; 183(1):173-6. PubMed ID: 19913835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
